6 research outputs found
Journal of Cardiovascular Magnetic Resonance
Oral presentation Myocardial fibrosis by delayed enhancement cardiovascular magnetic resonance and HCV infection in thalassemia major patient
Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial
A multicentre randomized open-label trial was designed to assess the
effectiveness of long-term sequential deferiprone\u2013deferoxamine (DFO\u2013DFP)
versus DFP alone to treat thalassaemia major (TM). DFP at 75 mg/kg,
divided into three oral daily doses, for 4 d/week and DFO by subcutaneous
infusion (8\u201312 h) at 50 mg/kg per day for the remaining 3 d/week was
compared with DFP alone at 75 mg/kg, administered 7 d/week during a
5-year follow-up. The main outcome measures were differences between
multiple observations of serum ferritin concentrations. Secondary outcomes
were survival analysis, adverse events, and costs. Consecutive thalassaemia
patients (275) were assessed for eligibility; 213 of these were randomized and
underwent intention-to-treat analysis. The decrease of serum ferritin levels
during the treatment period was statistically significant higher in sequential
DFP\u2013DFO patients compared with DFP-alone patients (P = 0.005). Kaplan\u2013
Meier survival analysis for the two chelation treatments did not show any
statistically significant differences (log-rank test, P = 0.3145). Adverse
events and costs were comparable between the groups. The trial results
show that sequential DFP\u2013DFO treatment compared with DFP alone
significantly decreased serum ferritin concentration during treatment for
5 years without significant differences regarding survival, adverse events,
or costs